{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:55:48Z","timestamp":1792133748511,"version":"4.4.0"},"reference-count":36,"publisher":"Wiley","issue":"28","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"publisher","award":["12275141"],"award-info":[{"award-number":["12275141"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 67\u2010year\u2010old male patient presented with extensive\u2010stage small cell lung cancer with the primary lesion located in the right upper lung, accompanied by multiple metastases to the pleura and abdominal cavity with enlarged mediastinal lymph nodes. A combination therapy approach was used to target the patient's multiple systemic metastases after localized radiotherapy. The approach involved adoptive transfer of programmed death ligand 1 (PD\u2010L1) enhanced exogenous natural killer (NK) cells, along with antiangiogenic treatment. Allogeneic cord blood NK cells were infused back into the patient over two consecutive days. On the first day, the treatment was followed by a dose of 1200\u2009mg of atezolizumab. Subsequently, the patient received a daily dose of 10\u2009mg of anlotinib administered orally for 14\u2009days. This was followed by a 7\u2010day break, and each cycle lasted 21\u2009days. After delivering localized radiation to the primary lesion in the right lung and metastatic mediastinal lymph nodes, complete remission was achieved in the local lesion, effectively avoiding the risk of superior vena cava syndrome. Following six cycles of combined therapy, most of the metastatic lesions had disappeared, and the remaining metastatic lesions had significantly reduced in size. The recent therapeutic effect resulted in partial remission. The combination therapy of immune checkpoint inhibitor PD\u2010L1\u2010enhanced exogenous adoptive transfer NK cells, along with antiangiogenic targeted treatment, demonstrated a satisfactory short\u2010term effect, with disappearance of most of the metastases and noticeable shrinkage in the remaining metastatic lesions.<\/jats:p>","DOI":"10.1111\/1759-7714.15040","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:14:18Z","timestamp":1692648858000},"page":"2877-2885","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Investigation of the efficacy and feasibility of combined therapy of <scp>PD\u2010L1<\/scp>\u2010enhanced exogenous peripatetic adoptive natural killer (<scp>NK)<\/scp> cells in combination with antiangiogenic targeted therapy in the treatment of extensive\u2010stage small cell lung cancer"],"prefix":"10.1111","volume":"14","author":[{"given":"Zhizhen","family":"Wang","sequence":"first","affiliation":[{"name":"Tianjin Medical University Cancer Institute &amp; Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5506-7016","authenticated-orcid":false,"given":"Ruiping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute &amp; Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchan","family":"Cao","sequence":"additional","affiliation":[{"name":"Brown University School of Public Health Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute &amp; Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute &amp; Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan'an","family":"Luo","sequence":"additional","affiliation":[{"name":"Nankai University  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002108"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2016.08.005"},{"key":"e_1_2_7_4_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology Small Cell Lung Cancer. (Version 3 2020)."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212033272302"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.2.336"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.008"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.004"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02212"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920982806"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.011"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.12.019"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30539-8"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00793"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.071"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.01.008"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.109"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01088-0"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01356-3"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-021-0916-8"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14414"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01279-7"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02869-9"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S337316"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11071040"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205046"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0426-7"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99317"},{"issue":"11","key":"e_1_2_7_32_1","article-title":"PD\u2010L1 blockade enhances anti\u2010tumor efficacy of NK cells","volume":"7","author":"Oyer JL","year":"2018","journal-title":"Onco Targets Ther"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132712"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.886440"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00348-8"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00492"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010164"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.15040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T23:26:19Z","timestamp":1696202779000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.15040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":36,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/1759-7714.15040"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.15040","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]},"assertion":[{"value":"2023-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}